MorphoSys AG / AbD Serotec Expands Sales Office in Düsseldorf to Support processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
AbD Serotec to Increase Sales Activities in Europe and Asia
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its
research and diagnostic antibodies unit AbD Serotec will expand its sales
organization in Düsseldorf to support growth in continental and eastern Europe
as well as in Asia. Today's official opening ceremony was performed by Friedrich
G. Conzen, major of Düsseldorf.
Dr. Simon Moroney, Chief Executive Officer of MorphoSys Group, also attended
along with Dieter Feger, Head of AbD Serotec. The expanded Düsseldorf office
will coordinate global sales activities of AbD Serotec outside North, Central
and South America.
"While we expect demand in our traditional markets to remain solid, we have
identified new areas of growth potential, and are now planning to expand our
sales outreach to increase our market share in eastern Europe and Asia, as well
as in our core market here in western Europe." commented Dieter Feger, Head of
AbD Serotec. "Our plans to add a telemarketing sales force and expand our direct
marketing efforts will act as central components of our growth strategy in these
markets."
According to MorphoSys's financial guidance, AbD Serotec is expected to
contribute roughly one quarter of total group revenues in 2009, driven by
above-market growth rates, with an operating profit margin of up to 6%.
MorphoSys expects the segment's financial performance to improve further in
2010. More specific financial guidance for 2010 will be given at the Company's
full year 2009 results presentation on February 25th, 2010.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visit http://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®) and RapMAT(®) are registered
trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors@morphosys.com
[HUG#1381767]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:MIDCAP,TecDAX,CDAX,TECH All Share,Prime All Share,HDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
PressRelease: http://hugin.info/130295/R/1381767/340889.pdf
